Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김충종 | - |
dc.date.accessioned | 2018-12-07T16:30:55Z | - |
dc.date.available | 2018-12-07T16:30:55Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0066-4804 | - |
dc.identifier.other | OAK-20453 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247470 | - |
dc.description.abstract | There are conflicting data on the association of vancomycin MIC (VANMIC) with treatment outcomes in Staphylococcus aureus infections. We investigated the relationship between high VAN-MIC and 30-day mortality and identified the risk factors for mortality in a large cohort of patients with invasive S. aureus (ISA) infections, defined as the isolation of S. aureus from a normally sterile site. Over a 2-year period, 1,027 adult patients with ISA infections were enrolled in 10 hospitals, including 673 (66%) patients with methicillin-resistant S. aureus (MRSA) infections. There were 200 (19.5%) isolates with high VAN-MIC (≥1.5 mg/liter) by Etest and 87 (8.5%) by broth microdilution (BMD). The all-cause 30-day mortality rate was 27.4%. High VAN-MIC by either method was not associated with all-cause 30-day mortality, and this finding was consistent across MIC methodologies and methicillin susceptibilities. We conclude that high VAN-MIC is not associated with increased risk of all-cause 30-day mortality in ISA infections. Our data support the view that VAN-MIC alone is not sufficient evidence to change current clinical practice. Copyright © 2017 American Society for Microbiology. All Rights Reserved. | - |
dc.language | English | - |
dc.publisher | American Society for Microbiology | - |
dc.subject | Bacteremia | - |
dc.subject | Methicillin resistant | - |
dc.subject | Methicillin susceptible | - |
dc.subject | MIC | - |
dc.subject | Staphylococcus aureus | - |
dc.subject | Vancomycin | - |
dc.title | Impact of vancomycin MIC on treatment outcomes in invasive Staphylococcus aureus infections | - |
dc.type | Article | - |
dc.relation.issue | 3 | - |
dc.relation.volume | 61 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.journaltitle | Antimicrobial Agents and Chemotherapy | - |
dc.identifier.doi | 10.1128/AAC.01845-16 | - |
dc.identifier.wosid | WOS:000394605900055 | - |
dc.identifier.scopusid | 2-s2.0-85014223195 | - |
dc.author.google | Song K.-H. | - |
dc.author.google | Kim M. | - |
dc.author.google | Kim C.J. | - |
dc.author.google | Cho J.E. | - |
dc.author.google | Choi Y.J. | - |
dc.author.google | Park J.S. | - |
dc.author.google | Ahn S. | - |
dc.author.google | Jang H.-C. | - |
dc.author.google | Park K.-H. | - |
dc.author.google | Jung S.-I. | - |
dc.author.google | Yoon N. | - |
dc.author.google | Kim D.-M. | - |
dc.author.google | Hwang J.-H. | - |
dc.author.google | Lee C.S. | - |
dc.author.google | Lee J.H. | - |
dc.author.google | Kwak Y.G. | - |
dc.author.google | Kim E.S. | - |
dc.author.google | Park S.Y. | - |
dc.author.google | Park Y. | - |
dc.author.google | Lee K.S. | - |
dc.author.google | Lee Y.-S. | - |
dc.author.google | Kim H.B. | - |
dc.contributor.scopusid | 김충종(56438092200) | - |
dc.date.modifydate | 20210915132750 | - |